Skip to main content
Premium Trial:

Request an Annual Quote

TATAA Biocenter Using Ingenuity Systems Software in HT Gene Expression Profiling

Premium

TATAA Biocenter said today that it has begun using Ingenuity Systems' iReport software in high-throughput gene expression profiling workflows.

The combined solution enables TATAA Biocenter's laboratories to provide contract research for a full range of real-time qPCR services — including primer and probe design, validation, kit and instrument evaluation, and biological and statistical analysis.

TATAA Biocenter offers all of the instrumentation and sample handing necessary to perform high-quality qPCR experiments, and meets specific requirements for compliance with ISO 17025. Ingenuity iReport enables researchers to quickly and easily identify significant differentially expressed genes and interpret the impact of those expression changes in the context of pathways, phenotypes, and molecular interactions.

Mikael Kubista, founder and CEO of TATAA Biocenter, said in a statement that TATAA decided on iReport for pathway analysis because it provides a "smooth workflow" with data collected on the biocenter's Life Technologies OpenArray and Fluidigm BioMark high-throughput qPCR platforms; reads batchwise into GenEx software for multivariate statistical analysis, and provides "an easy, accurate, web-based biological and statistical interpretation tool."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more